Literature DB >> 21703190

Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants.

Julien Namur1, Steven J Citron, Marty T Sellers, Mark H Dupuis, Michel Wassef, Michel Manfait, Alexandre Laurent.   

Abstract

BACKGROUND & AIMS: To follow the local tissue delivery of doxorubicin in HCC explants from patients embolized with drug-eluting beads and to compare it with histologic modifications.
METHODS: Six patients with HCC underwent chemoembolization with doxorubicin-eluting beads (caliber 100-300 μm, dose 75-150 mg) followed by liver transplantation at different time points (8 h to 36 days). On sections of the explanted liver, the tissue concentration of doxorubicin was determined radially around bead-occluded vessels with microspectrofluorimetry. The intra/peritumoral location of the beads and the modifications of the surrounding tissue were determined on an adjacent hematein-eosin-saffron-stained section and compared to drug measurements.
RESULTS: Doxorubicin was detected in the tissue surrounding the beads at all times of explantation. The drug impregnates an area of at least 1.2 mm in diameter around the occluded vessel. The tissue concentration of drug ranges from 5 μM at 8 h to 0.65 μM at 1 month. In patient transplanted at 8 h, no major tissue modification was observed and we found 42% of the beads occluding intratumoral vessels. Drug concentration was not different around intratumoral and peritumoral occluded vessels. After 9-14 days, necrosis was present around 37% of vessels and at 32-36 days, around 40% of vessels. Necrotic tissue was associated with a deeper penetration and a higher concentration of the drug than non necrotized areas, though statistically significant only at 32-36 days.
CONCLUSIONS: Doxorubicin-eluting beads provide a sustained delivery of drug for a period of 1 month and local tissue concentrations above cytotoxic threshold in HCC-bearing livers.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703190     DOI: 10.1016/j.jhep.2011.03.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  57 in total

1.  [Intra-arterial treatment of liver metastases from colorectal carcinoma].

Authors:  O Pellerin; J-F Geschwind
Journal:  J Radiol       Date:  2011-09-01

2.  Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma: does size really matter?

Authors:  Sieh-Yang Lee; Hsin-You Ou; Chun-Yen Yu; Tung-Liang Huang; Leo Leung-Chit Tsang; Yu-Fan Cheng
Journal:  Diagn Interv Radiol       Date:  2020-05       Impact factor: 2.630

Review 3.  Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy.

Authors:  Andrew L Lewis; Matthew R Dreher
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

4.  Does doxorubicin survive thermal ablation? Results of an ex vivo bench top study.

Authors:  Joseph D Morrison; Collin K Schlager; Amanda E Lee; Richard B van Breemen; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2018 Jan-Feb       Impact factor: 2.630

Review 5.  Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.

Authors:  Samdeep K Mouli; Laura W Goff
Journal:  Curr Treat Options Oncol       Date:  2017-10-27

Review 6.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

Review 7.  Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

Authors:  Thierry de Baere; Lambros Tselikas; Frederic Deschamps; Valerie Boige; Michel Ducreux; Antoine Hollebecque
Journal:  Hepat Oncol       Date:  2016-03-23

Review 8.  Chemoembolization with DC Bead™ for the treatment of hepatocellular carcinoma: an update.

Authors:  Katerina Malagari; Emmanouil Emmanouil; Maria Pomoni; Dimitrios Kelekis
Journal:  Hepat Oncol       Date:  2014-03-20

9.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.

Authors:  Pi-Yi Chang; Chun-Chieh Huang; Chao-Hung Hung; Chih-Yung Yu; Ding-Kwo Wu; Jen-I Hwang; Po-Chin Liang; Reng-Hong Wu; Wei-Lun Tsai; Yih-Jyh Lin; Yi-Sheng Liu; Huei-Lung Liang; Rheun-Chuan Lee; Chien-Hung Chen
Journal:  Liver Cancer       Date:  2018-03-29       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.